Admera Health CardioGxOne Panel

Nov 10, 2015

Admera Health has launched the CardioGxOne next-generation sequencing panel for inherited cardiovascular disease. Developed as a joint venture between Admera Health and Health in Code, the test detects genomic variations in 213 genes related to familial cardiovascular diseases, and is designed to detect the genetic causes of sudden death in young individuals and athletes, such as cardiomyopathies, long QT, and Marfan syndrome. CardioGxOne combines the genetic and clinical information of more than 85,000 individuals from a proprietary database with a comprehensive interpretive report that is reviewed by specialized cardiology geneticists, Admera said.

Admera Health CardioGxOne Panel

Cerebral Palsy Sequencing Study Finds Clinically Actionable Alterations

Lucid Diagnostics Raises $22M in Convertible Debt Refinancing

Medicover Genetics Receives IVDR Certification for Genetic Testing Reagent Kit

Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint

Multi-Ancestry Study Uncovers Genetic Contributors to Progressive Eye Disease